Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Dyadic Solutions
Jupiter, Florida, United Statesdyadic.solutions ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Dyadic’s lead product ("DNAS1") is in NDA preparation/review. The company has active collaborations to develop monoclonal antibodies against RSV and malaria using its C1 platform, supported by a Gates Foundation grant. Other pipeline programs include recombinant proteins for cell culture media, diagnostics, food/nutrition applications, and legacy biopharmaceutical projects.[2][4][5][7]
- Therapeutic areas
- Infectious Diseases
- Modalities
- Recombinant proteinMonoclonal antibodyVaccine (biologic)
- Industry
- Biotech
02
Partnerships
Bill & Melinda Gates Foundation [5][7]Coalition for Epidemic Preparedness Innovations (CEPI) [5]Fondazione Biotecnopolo di Siena [5]
Beyond the preview
Go deeper on Dyadic Solutions.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dyadic Solutions.